Aerococcaceae: The Emerging Pathogen with Paradoxical Probiotic Potential

The family Aerococcaceae represents a fascinating duality in clinical microbiology: a group of bacteria historically regarded as environmental contaminants that are now recognized as both emerging human pathogens and, paradoxically, as potential probiotic candidates. This family comprises Gram-positive, catalase-negative cocci that inhabit diverse environments ranging from hospital settings to marine sites, with several species capable of causing significant human infections including urinary tract infections, bacteremia, and infective endocarditis.

For decades, Aerococcus species were misidentified as streptococci, staphylococci, or enterococci due to their similar morphological and biochemical characteristics, leading to a substantial underestimation of their clinical significance. The advent of matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) has revolutionized their identification, revealing that Aerococcus urinae and Aerococcus sanguinicola are far more common causes of both urinary tract infections and invasive disease than previously appreciated.

Recent research from 2025 has dramatically expanded our understanding of this family. A nationwide Swedish study established the population-level incidence of aerococcal bloodstream infections at 1.48 per 100,000 person-years, with striking predilection for elderly men with underlying urologic conditions. Simultaneously, groundbreaking in vitro research has revealed that Aerococcus viridans possesses unexpected probiotic properties, including antimicrobial activity against pathogens, antioxidant capabilities, and even anti-colon cancer activity through induction of apoptosis in HT-29 cancer cells. This paradoxical nature positions the Aerococcaceae family as a subject of intense scientific interest, straddling the boundary between pathogen and potential therapeutic agent.

The family encompasses eight genera, with Aerococcus being the most clinically significant, comprising species including A. urinae, A. sanguinicola, A. viridans, A. christensenii, and A. urinaehominis. Their ecology remains incompletely understood, but they appear to colonize various niches including the human urinary and reproductive tracts, animal gastrointestinal systems, and environmental reservoirs.

---

Where It Is Found

Human Habitat

Aerococcus species colonize multiple sites in the human body, though their natural reservoir remains incompletely characterized. They are most frequently isolated from the urinary tract, where they can exist as commensals or transition to pathogens causing symptomatic infection. The urinary tract is the primary source of aerococcal bacteremia, identified as the likely source in 50 percent of cases based on imaging findings, positive urine cultures, or instrumentation history.

The female reproductive tract may also serve as a colonization site, with related species identified in bovine vaginal mucosa, suggesting potential for similar colonization in humans.

Animal Reservoirs

Aerococcus viridans is a significant pathogen in veterinary medicine, causing bovine mastitis with substantial economic impact. In a South Korean study of 1,774 mastitis milk samples collected between 2016 and 2021, 3.9 percent yielded A. viridans isolates. These infections were associated with significantly elevated somatic cell counts, with 80.5 percent associated with subclinical mastitis and 19.5 percent with clinical disease. The bacterium has also been isolated from Nile tilapia (Oreochromis niloticus), indicating broad host range across aquatic and terrestrial animals.

Environmental Sources

Members of the Aerococcaceae family inhabit diverse environmental niches including household environments, schoolrooms, yard and street settings, hospital environments, and marine sites. This environmental ubiquity may explain their occasional isolation from clinical specimens and their role as opportunistic pathogens.

Geographic Distribution

Aerococcal infections occur worldwide, with population-based studies demonstrating consistent patterns across geographic regions. The Swedish nationwide study spanning 39.6 million person-years documented 588 episodes of aerococcal bloodstream infection, establishing baseline incidence and risk factor profiles applicable to Western populations.

Factors Affecting Colonization and Infection

· Age: Infections predominantly affect elderly individuals, with median age 74.3 years in clinical series

· Sex: Male predominance is striking, with most studies reporting 60 to 75 percent male patients

· Urologic conditions: Recurrent urinary tract infection, urinary incontinence, indwelling catheters, renal stones, and benign prostatic hyperplasia are key risk factors

· Neurologic conditions: Associated with 2.89-fold increased risk of aerococcal bloodstream infection

· Previous hospitalization or infection treatment: Significantly increases susceptibility

---

1. Taxonomic Insights

Scientific Name: Aerococcus spp. (Family Aerococcaceae)

Family: Aerococcaceae Ludwig et al. 2010

Phylum: Bacillota (formerly Firmicutes)

Taxonomic Note

The family Aerococcaceae was formally described in 2009 with validation published in 2010, established on the basis of phylogenetic analyses of 16S rRNA gene sequences. The family circumscription includes the genus Aerococcus and its close relatives, distinguished from other members of the order Lactobacillales by unique phylogenetic position and phenotypic characteristics. The genus name Aerococcus derives from Greek, meaning "air coccus," reflecting its initial isolation from environmental sources.

The type genus is Aerococcus, with the family name formed by adding the suffix -aceae to denote a family. The etymology reflects the naming convention: N.L. masc. n. Aerococcus, type genus of the family; suff. -aceae, ending to denote a family; N.L. fem. pl. n. Aerococcaceae, the Aerococcus family.

Family Characteristics

Members of the Aerococcaceae are defined by the following characteristics:

· Gram-positive ovoid cocci or coccobacilli

· Nonmotile, lacking flagella

· Endospores are not formed

· Facultatively anaerobic, capable of growth in both aerobic and anaerobic conditions

· Catalase-negative, distinguishing them from staphylococci and micrococci

· Cell walls contain the diamino acid lysine in the peptidoglycan

· Capable of growth in media containing 6.5 percent sodium chloride

Genera Within the Family

The Aerococcaceae family comprises eight genera:

· Aerococcus: The type genus, containing the most clinically significant species

· Abiotrophia: Formerly considered nutritionally variant streptococci

· Dolosicoccus: Rarely isolated from clinical specimens

· Eremococcus: Environmental species with unclear clinical significance

· Facklamia: Named for microbiologist Richard Facklam, isolated from clinical sources

· Globicatella: Associated with human infections including bacteremia

· Ignavigranum: Rare isolates from human specimens

Clinically Significant Species

· Aerococcus urinae: The most common human pathogen in the genus, associated with urinary tract infections, bacteremia, and infective endocarditis. Accounts for approximately 50 percent of aerococcal bloodstream isolates.

· Aerococcus sanguinicola: Second most common pathogen, similarly associated with urinary tract infections and invasive disease. The species name reflects its isolation from blood (sanguis, blood).

· Aerococcus viridans: The type species of the genus, originally described in 1953. Causes bovine mastitis and occasional human infections. Exhibits alpha-hemolysis on blood agar, contributing to its historical misidentification as streptococci.

· Aerococcus christensenii: Named in honor of Danish microbiologist J.J. Christensen, rarely isolated from human infections.

· Aerococcus urinaehominis: Isolated from human urine, uncommon cause of symptomatic infection.

Taxonomic Challenges and Recent Developments

The taxonomy of Aerococcus species has been complicated by difficulties in phenotypic differentiation and historical misidentification. Recent genomic analyses have revealed greater species diversity than previously recognized, with proposals to subdivide A. urinae into multiple species including A. urinae sensu stricto, A. tenax, A. mictus, and A. loyolae. Whole genome analysis provides clearer species boundaries than 16S rRNA gene sequencing alone.

---

2. Therapeutic Actions

Primary Actions (as Potential Probiotic)

· Antimicrobial activity against bacterial and fungal pathogens

· Hydrogen peroxide production (mechanism of antagonism)

· Antioxidant activity (free radical scavenging)

· Anti-cancer activity (colon cancer cell apoptosis induction)

· Gut barrier support potential

Secondary Actions

· Immunomodulation (limited evidence)

· Biofilm formation capacity (context-dependent)

· Competitive exclusion of pathogens

Note on Therapeutic Context

The therapeutic actions described below derive primarily from in vitro studies of Aerococcus viridans isolates, particularly strain 167, and should be considered investigational. Aerococcus species are not currently approved as probiotics for human use, and their clinical application requires further safety evaluation.

---

3. Bioactive Components and Their Action

Hydrogen Peroxide

Hydrogen peroxide production represents a primary mechanism of antagonistic activity against pathogenic microorganisms.

· Production Mechanism: Hydrogen peroxide generation in aerococci is mediated by NAD-independent lactatoxidase, an enzyme that catalyzes the oxidation of lactate with concomitant reduction of oxygen to hydrogen peroxide.

· Antimicrobial Activity: Hydrogen peroxide exerts broad-spectrum antimicrobial effects against Gram-positive and Gram-negative bacteria, contributing to the antagonistic activity of A. viridans against pathogens including Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli, Proteus vulgaris, Klebsiella ozaenae, Citrobacter freundii, Pseudomonas aeruginosa, and Candida albicans.

· Concentration Dependence: Strain 167 showed the highest indicators of hydrogen peroxide production among tested aerococci strains, making it particularly suitable for probiotic applications.

Antioxidant Enzymes

Aerococci possess a sophisticated antioxidant defense system that protects against both endogenous and exogenous reactive oxygen species.

· Superoxide Dismutase: Provides defense against superoxide radicals generated during aerobic metabolism and host immune responses.

· Glutathione Peroxidase: Contributes to the neutralization of hydrogen peroxide and organic hydroperoxides, protecting bacterial cells from oxidative damage.

· Functional Integration: The coordinated activity of these enzymes enables aerococci to survive in oxidative environments and may contribute to their ability to persist in host tissues.

Cell-Free Supernatant Bioactive Factors

The cell-free supernatant of A. viridans contains multiple bioactive compounds with therapeutic potential.

· Antimicrobial Factors: Beyond hydrogen peroxide, the supernatant contains uncharacterized antimicrobial compounds active against Bacillus subtilis, Klebsiella pneumoniae, and Candida albicans. The supernatant demonstrates broad-spectrum activity that may complement live bacterial effects.

· Antioxidant Activity: Concentration-dependent scavenging activity demonstrated in DPPH and ABTS assays, indicating the presence of soluble antioxidant compounds.

· Anti-Cancer Activity: The cell-free supernatant exhibits potent anti-colon cancer activity against HT-29 cells with an IC50 of 25 ± 1.5 micrograms per milliliter. Activity is concentration-dependent, with 58.69 percent apoptosis induction at 50 micrograms per milliliter.

Apoptosis-Inducing Components

Research published in 2025 identified that A. viridans cell-free supernatant induces apoptosis in colon cancer cells through mechanisms involving cell cycle arrest.

· Mechanism of Action: AO/EtBr and DAPI staining revealed significant reduction in viable cancer cells following supernatant treatment. Cell cycle analysis demonstrated a significant increase of cells arrested in G0/G1 phase with corresponding decrease in G2/M phase, indicating cell cycle disruption.

· Apoptosis Induction: The observed 58.69 percent apoptosis at 50 micrograms per milliliter suggests the presence of potent apoptosis-inducing compounds that warrant further characterization.

· Therapeutic Implications: These findings position A. viridans supernatant as a potential alternative for cancer prevention, though in vivo studies are required to validate efficacy and safety.

Cell Wall Components

The Gram-positive cell wall architecture of aerococci contains lysine in the peptidoglycan, distinguishing them from related families that utilize diaminopimelic acid.

· Peptidoglycan Structure: Contains the diamino acid lysine as the diagnostic component, characteristic of the family.

· Immunomodulatory Potential: As with other Gram-positive bacteria, cell wall components may interact with host pattern recognition receptors, though specific immunomodulatory effects of aerococcal cell wall components remain poorly characterized.

---

4. Clinical and Therapeutic Applications

Emerging Probiotic Applications

Antimicrobial Activity Against Pathogens

Research has demonstrated that A. viridans, particularly strain 167, exhibits potent antagonistic activity against a wide range of pathogenic microorganisms.

· Broad-Spectrum Activity: The combination of A. viridans 167 with Bacillus subtilis 3 shows synergistic antimicrobial effects against both museum and clinical strains of multiple pathogens including Escherichia coli, Proteus vulgaris, Klebsiella ozaenae, Citrobacter freundii, Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus epidermidis, and Candida albicans.

· Superiority Over Single Strains: The associative combination of A. viridans 167 and B. subtilis 3 demonstrates greater antagonistic effect than either strain alone, supporting the rationale for multi-strain probiotic formulations.

· Resistance Profile: A. viridans shows sensitivity to gentamicin and vancomycin but resistance to several other antibiotics, an important safety consideration for probiotic applications.

Anti-Cancer Activity

The 2025 discovery of anti-colon cancer activity represents a paradigm-shifting finding for the genus.

· In Vitro Efficacy: Cell-free supernatant from A. viridans isolated from Nile tilapia exhibits concentration-dependent cytotoxicity against HT-29 colon cancer cells with IC50 of 25 micrograms per milliliter.

· Apoptosis Mechanism: Cancer cell death occurs through apoptosis, with 58.69 percent of cells undergoing programmed cell death at 50 micrograms per milliliter concentration. Cell cycle analysis confirms G0/G1 phase arrest.

· Potential Applications: These findings suggest A. viridans supernatant may have utility as a cancer prevention or adjunctive therapy, though human studies are required.

Antioxidant Applications

The concentration-dependent antioxidant activity of A. viridans supernatant suggests potential applications in oxidative stress-related conditions.

· Free Radical Scavenging: DPPH and ABTS assays demonstrate significant antioxidant capacity that increases with concentration.

· Mechanistic Basis: Antioxidant activity may derive from multiple components including enzymatic and non-enzymatic factors.

Gastrointestinal Health

As a potential probiotic, A. viridans may support gastrointestinal tract barrier function.

· Barrier Maintenance: Probiotics can influence gut microbiota composition and aid in maintaining a healthy gastrointestinal tract barrier.

· Dysbiosis Correction: A. viridans is being evaluated as a component of associative probiotic complexes for correction of gastrointestinal dysbiosis.

Pathogenic Considerations

Urinary Tract Infections

Aerococcus species, particularly A. urinae and A. sanguinicola, are established uropathogens causing both uncomplicated and complicated urinary tract infections.

· Clinical Presentation: Many patients with bacteriuria involving aerococci experience symptoms of urinary tract infection, including dysuria, frequency, and urgency.

· Diagnostic Challenges: Aerococci are easily misidentified as alpha-hemolytic streptococci, leading to underdiagnosis. MALDI-TOF MS provides accurate identification.

· Treatment Considerations: Optimal treatment regimens remain incompletely defined. Uncertainty exists regarding the effectiveness of trimethoprim-sulfamethoxazole, fluoroquinolones, and nitrofurantoin. Penicillin is appropriate for invasive infections.

Bacteremia and Invasive Disease

Aerococcal bloodstream infections, while uncommon, carry significant morbidity and mortality.

· Epidemiology: Nationwide Swedish study documented 588 episodes over 39.6 million person-years, incidence 1.48 per 100,000 person-years.

· Risk Factors: Neurologic conditions (adjusted odds ratio 2.89), urologic conditions (adjusted odds ratio 2.15), previous hospitalization, and prior infection treatment.

· Clinical Features: Presenting symptoms include fever (75 percent of cases) and altered mentation (30 percent). Median hospital stay 6.55 days, with 10 percent mortality in some series.

· Source Identification: Urinary tract identified as likely source in 50 percent of cases based on imaging or culture.

Infective Endocarditis

Aerococcus urinae and A. sanguinicola cause infective endocarditis with significant mortality.

· Clinical Suspicion: Endocarditis should be considered in all aerococcal bacteremia cases, with 45 percent of patients in one series having suspected endocarditis.

· Echocardiographic Findings: Transesophageal echocardiography confirmed endocarditis in 15 percent of cases in one series, involving aortic valves, mitral valves, and pacemaker leads.

· Treatment: Penicillin is appropriate, with addition of an aminoglycoside for endocarditis. Valve replacement may be required in complicated cases.

· Prognosis: Despite treatment, mortality occurs, with 2 of 20 patients (10 percent) in one series succumbing to infection.

Veterinary Pathogenicity

Aerococcus viridans is a significant pathogen in dairy cattle, causing mastitis with economic consequences.

· Disease Burden: Present in 3.9 percent of mastitis milk samples in South Korean study, with 80.5 percent associated with subclinical mastitis.

· Biofilm Formation: 78.3 percent of isolates capable of biofilm formation, with all recent isolates being biofilm-positive, suggesting adaptation to the bovine mammary gland environment.

· Antimicrobial Resistance: High resistance rates to ceftiofur (46.4 percent), oxacillin (44.9 percent), tetracycline (36.2 percent), with 21.7 percent of isolates multidrug-resistant.

· Genetic Diversity: Substantial genetic diversity with no dominant clones identified, complicating control efforts.

---

5. Therapeutic Preparations and Formulations

Investigational Probiotic Preparations

Live Biotherapeutic Product Candidates

· Strain Selection: A. viridans 167 has been selected for inclusion in probiotic preparations based on its high hydrogen peroxide production, antimicrobial activity, and compatibility with other probiotic strains.

· Compatibility Testing: No mutual antagonism detected between A. viridans 167 and Bacillus subtilis 3 during co-cultivation, supporting multi-strain formulation.

· Safety Considerations: The strain shows resistance to lysozyme, bile salts, and pH variations, indicating potential for gastrointestinal survival.

Associative Probiotic Complexes

· Rationale: Combination preparations may feature higher efficiency than single-species probiotics due to synergistic effects.

· Formulation: A. viridans 167 combined with B. subtilis 3 shows enhanced antimicrobial activity against multiple pathogens compared to either strain alone.

· Target Indications: Dysbiosis correction, gastrointestinal health maintenance, and potentially cancer prevention.

Cell-Free Supernatant Formulations

· Preparation: Cell-free supernatant can be harvested from cultured A. viridans and concentrated for therapeutic applications.

· Anti-Cancer Potential: The concentration-dependent activity against HT-29 cells suggests potential for supernatant-based cancer therapeutics.

· Antioxidant Applications: Supernatant antioxidant activity supports potential use in oxidative stress-related conditions.

Production Considerations

Culture Conditions

· A. viridans requires appropriate growth conditions for optimal bioactive compound production

· Strain 167 produces high levels of hydrogen peroxide under suitable culture conditions

· Cell-free supernatant bioactivity is concentration-dependent, requiring optimization of production parameters

Standardization

· Bioactivity assays (antimicrobial, antioxidant, anti-cancer) required for batch-to-batch consistency

· Hydrogen peroxide production serves as a key quality indicator

· Supernatant composition may vary with culture conditions

Regulatory Status

Aerococcus species are not currently approved as probiotics for human consumption in major regulatory jurisdictions. Their status as emerging pathogens necessitates careful safety evaluation before therapeutic use. The paradoxical nature of the genus, with both pathogenic and potential probiotic properties, requires comprehensive risk-benefit assessment.

---

6. In-Depth Mechanistic Profile and Clinical Significance

The Dual Nature: Pathogen and Probiotic Candidate

The Aerococcaceae family occupies an unusual position in clinical microbiology, embodying the complex relationship between commensal bacteria and their hosts. Unlike traditional probiotic organisms with long histories of safe use, aerococci exhibit clear pathogenic potential in vulnerable populations. Yet recent research has uncovered properties that, under different contexts, could be harnessed for therapeutic benefit.

The pathogenic manifestations are well documented. Aerococcus urinae and A. sanguinicola cause symptomatic urinary tract infections, bacteremia, and life-threatening endocarditis, primarily affecting elderly men with underlying urologic conditions. The Swedish nationwide study established population-level incidence of 1.48 per 100,000 person-years, with significant mortality in invasive cases. Antimicrobial resistance patterns show high rates of resistance to ceftiofur, tetracycline, and other agents, complicating treatment.

Paradoxically, the same genus exhibits properties traditionally associated with beneficial probiotics. A. viridans produces hydrogen peroxide via NAD-independent lactatoxidase, exerting broad-spectrum antimicrobial activity against Gram-positive and Gram-negative bacteria as well as fungi. Its antioxidant enzyme system, including superoxide dismutase and glutathione peroxidase, protects against oxidative stress. Most remarkably, the 2025 discovery of anti-colon cancer activity with 58.69 percent apoptosis induction at 50 micrograms per milliliter suggests therapeutic potential far beyond traditional probiotic applications.

Hydrogen Peroxide as a Dual-Edged Mechanism

Hydrogen peroxide production exemplifies the duality of aerococci. As a mechanism of antagonism against pathogens, it contributes to the probiotic potential of the organism, inhibiting growth of Escherichia coli, Staphylococcus aureus, Candida albicans, and other clinically significant microorganisms. The superior hydrogen peroxide production of strain 167 makes it particularly attractive for probiotic applications.

However, hydrogen peroxide also contributes to tissue damage and inflammation in the context of infection. In bovine mastitis, the presence of A. viridans is associated with elevated somatic cell counts, indicating inflammatory response. The balance between beneficial antimicrobial effects and potential tissue damage requires careful evaluation for any therapeutic application.

Biofilm Formation: Virulence Factor or Colonization Advantage?

The capacity for biofilm formation in A. viridans isolates from bovine mastitis presents another duality. Biofilm formation enables persistence in host environments, protecting bacteria from host immune responses and antimicrobial agents. In the context of mastitis, biofilm formation likely contributes to chronic infection and treatment failure.

Conversely, biofilm formation could represent a colonization advantage for probiotic applications, enabling persistence in the gastrointestinal tract and prolonged therapeutic effects. The finding that all recent isolates are biofilm-positive compared to earlier non-producers suggests adaptation to the bovine mammary gland, highlighting the context-dependent nature of this trait.

Genomic Diversity and Species Differentiation

Whole genome analysis has revealed substantial genomic diversity within the genus, with proposals to subdivide A. urinae into multiple species. This genomic diversity likely underlies phenotypic variation in pathogenicity, antimicrobial resistance, and potential probiotic properties.

The development of A. viridans 167 for probiotic applications requires careful genomic characterization to ensure absence of acquired virulence factors or transferable antimicrobial resistance genes. The finding that clinical isolates show high rates of antimicrobial resistance, including multidrug resistance in 21.7 percent of bovine mastitis isolates, underscores the importance of strain selection and safety assessment.

The Urinary Tract Niche: Colonization to Invasion

The urinary tract represents the primary site of aerococcal colonization and infection. Risk factors for invasive disease include urologic abnormalities, indwelling catheters, and recurrent urinary tract infections. The transition from colonization to invasion likely involves host factors, bacterial virulence determinants, and the urobiome context.

Understanding the molecular mechanisms of urinary tract colonization and invasion could inform both treatment of infections and development of probiotic strategies. If aerococci can be engineered or selected to retain beneficial properties while losing pathogenic potential, they might serve as effective urogenital probiotics.

Antioxidant Defense and Therapeutic Potential

The antioxidant enzyme system of aerococci, including superoxide dismutase and glutathione peroxidase, protects against oxidative stress and may contribute to survival in host tissues. These enzymes could potentially be harnessed for therapeutic applications in oxidative stress-related conditions.

The concentration-dependent antioxidant activity of cell-free supernatant, demonstrated by DPPH and ABTS assays, suggests the presence of soluble antioxidant factors that could be developed as therapeutic agents. The antioxidant capacity increases with concentration, indicating dose-dependent effects suitable for pharmaceutical development.

Apoptosis Induction in Cancer Cells

The 2025 discovery that A. viridans cell-free supernatant induces apoptosis in HT-29 colon cancer cells opens new avenues for cancer therapeutic development. The IC50 of 25 micrograms per milliliter represents potent activity, with 58.69 percent apoptosis induction at 50 micrograms per milliliter.

Cell cycle analysis revealing G0/G1 phase arrest with corresponding decrease in G2/M phase indicates specific disruption of cancer cell proliferation. The mechanism appears to involve apoptosis rather than necrosis, as confirmed by AO/EtBr and DAPI staining, suggesting programmed cell death pathways.

The identity of the apoptosis-inducing compound or compounds remains unknown, representing a priority for future research. Characterization of the active principle could lead to development of novel anti-cancer agents.

---

7. Dietary and Lifestyle Considerations

No Established Dietary Strategies for Aerococcus Modulation

Unlike beneficial commensals such as Akkermansia muciniphila or Adlercreutzia equolifaciens, there are no established dietary strategies to selectively enhance Aerococcus species in the gut microbiome. Aerococci are not considered target organisms for enrichment through dietary interventions.

General Urinary Tract Health

Given the predilection of aerococci for the urinary tract, measures to maintain urinary tract health may reduce infection risk.

· Adequate hydration to maintain urinary flow

· Prompt treatment of urinary tract infections

· Avoidance of unnecessary urinary catheterization

· Management of underlying urologic conditions

Antibiotic Stewardship

Given the high rates of antimicrobial resistance among clinical isolates, prudent antibiotic use is essential.

· Avoid unnecessary antibiotic prescriptions

· Complete prescribed courses when antibiotics are necessary

· Consider antimicrobial susceptibility testing for aerococcal infections

Infection Prevention in High-Risk Populations

Elderly men with urologic conditions are at highest risk for aerococcal infections.

· Regular monitoring for urinary tract symptoms

· Prompt evaluation of fever or altered mental status

· Consideration of aerococci as potential pathogens in appropriate clinical contexts

---

8. Foods and Factors to Limit

No Specific Dietary Factors

Unlike many beneficial gut commensals, there are no known dietary factors that selectively increase or decrease Aerococcus abundance. The family's ecological niche remains incompletely characterized, limiting dietary recommendations.

Risk Factors for Aerococcal Infection

The following factors are associated with increased risk of aerococcal infection rather than dietary influences:

· Advanced age

· Male sex

· Urologic conditions (recurrent urinary tract infection, incontinence, indwelling catheter, renal stones, benign prostatic hyperplasia)

· Neurologic conditions

· Previous hospitalization

· Prior infection treatment

· Urinary tract instrumentation

Antibiotic Exposure

Antibiotic exposure, particularly to agents with limited activity against aerococci, may select for these organisms in the urinary tract.

· Broad-spectrum antibiotics disrupt normal microbiota

· Antimicrobial resistance in aerococci may be selected by prior antibiotic use

· Judicious antibiotic use may reduce risk of aerococcal overgrowth

---

9. Therapeutic Potential in Specific Conditions: A Summary

Colon Cancer

A. viridans cell-free supernatant shows potent anti-colon cancer activity in vitro with IC50 of 25 micrograms per milliliter against HT-29 cells. Apoptosis induction reaches 58.69 percent at 50 micrograms per milliliter with G0/G1 cell cycle arrest. This represents a novel discovery requiring in vivo validation and characterization of active compounds.

Bacterial and Fungal Infections

A. viridans demonstrates broad-spectrum antimicrobial activity against Gram-positive bacteria (Staphylococcus aureus, S. epidermidis), Gram-negative bacteria (Escherichia coli, Proteus vulgaris, Klebsiella ozaenae, Citrobacter freundii, Pseudomonas aeruginosa), and fungi (Candida albicans). The activity is enhanced in combination with Bacillus subtilis 3, supporting multi-strain probiotic approaches.

Oxidative Stress-Related Conditions

A. viridans cell-free supernatant exhibits concentration-dependent antioxidant activity in DPPH and ABTS assays. The presence of superoxide dismutase and glutathione peroxidase suggests potential applications in conditions involving oxidative damage.

Gastrointestinal Dysbiosis

A. viridans is being evaluated as a component of associative probiotic complexes for correction of gastrointestinal dysbiosis. Compatibility with B. subtilis supports multi-strain formulations for gut health.

Urinary Tract Infections (Pathogenic Context)

A. urinae and A. sanguinicola are established uropathogens requiring appropriate antimicrobial therapy. Penicillin is appropriate for invasive infections, with aminoglycoside addition for endocarditis. Treatment of uncomplicated urinary tract infections requires susceptibility testing due to uncertain activity of standard agents.

Infective Endocarditis

Aerococcal endocarditis requires aggressive management with penicillin and aminoglycoside, with potential need for valve replacement. Mortality occurs despite treatment, emphasizing the importance of early recognition.

---

10. Conclusion

The Aerococcaceae family represents one of the most intriguing paradoxes in contemporary microbiology. For decades dismissed as environmental contaminants or misidentified as more familiar pathogens, these bacteria are now recognized as significant emerging human pathogens, particularly among elderly men with urologic conditions. The 2025 Swedish nationwide study establishing population-level incidence and risk factors represents a major advance in understanding the clinical epidemiology of aerococcal bloodstream infections.

Simultaneously, groundbreaking research from the same year has revealed that Aerococcus viridans possesses properties traditionally associated with beneficial probiotics: broad-spectrum antimicrobial activity, concentration-dependent antioxidant effects, and most remarkably, potent anti-colon cancer activity with induction of apoptosis in HT-29 cells. The discovery that cell-free supernatant achieves 58.69 percent apoptosis at 50 micrograms per milliliter with cell cycle arrest opens entirely new avenues for cancer therapeutic development.

This duality raises fundamental questions about the nature of host-microbe relationships. How can the same genus cause life-threatening endocarditis in vulnerable patients while exhibiting anti-cancer properties in vitro? The answer likely lies in context: host factors including age, underlying conditions, and immune status; bacterial factors including species, strain, and genetic composition; and environmental factors including niche (urinary tract versus gastrointestinal tract) and microbial community context.

For clinicians, the Aerococcaceae family requires awareness and accurate identification. The development of MALDI-TOF MS has revolutionized diagnosis, revealing that aerococci are far more common than previously appreciated. Appropriate treatment of invasive infections with penicillin-based regimens can be life-saving, while recognition of risk factors enables targeted prevention strategies.

For researchers, the family offers rich opportunities. The anti-cancer mechanism of A. viridans supernatant demands characterization of active compounds and validation in animal models. The probiotic potential requires careful safety assessment given the pathogenic capacity of the genus. The genomic diversity revealed by whole genome analysis provides foundation for understanding virulence and beneficial properties.

The path forward for therapeutic applications of Aerococcus species must navigate this duality carefully. Strain selection is critical: the properties of A. viridans 167, including high hydrogen peroxide production, antimicrobial activity, and compatibility with other probiotics, must be balanced against safety considerations. Formulation strategies may focus on cell-free supernatant rather than live bacteria to harness beneficial effects while avoiding risks associated with viable organisms. Regulatory pathways for such unconventional probiotic candidates require development.

The Aerococcaceae family thus stands at the intersection of clinical microbiology, probiotic science, and cancer research. Its members challenge simple categorization as pathogens or commensals, revealing instead a nuanced relationship with human hosts that varies dramatically with context. As research continues to unravel the mechanisms underlying both pathogenicity and therapeutic potential, the family promises to yield insights that extend far beyond its own taxonomy, illuminating fundamental principles of host-microbe interactions and opening new therapeutic possibilities at the boundaries of traditional probiotic applications.

---

11. Reference Books for In-Depth Study

· Bergey's Manual of Systematic Bacteriology, Second Edition, Volume 3 (The Firmicutes) by Paul De Vos, George M. Garrity, Dorothy Jones, Noel R. Krieg, Wolfgang Ludwig, Fred A. Rainey, Karl-Heinz Schleifer, and William B. Whitman

· The Prokaryotes: Firmicutes and Tenericutes by Eugene Rosenberg, Edward F. DeLong, Stephen Lory, Erko Stackebrandt, and Fabiano Thompson

· Manual of Clinical Microbiology, 12th Edition by James H. Jorgensen, Michael A. Pfaller, Karen C. Carroll, Guido Funke, Melissa B. Miller, Sandra S. Richter, and David W. Warnock

· Infectious Diseases, 4th Edition by Jonathan Cohen, William G. Powderly, and Steven M. Opal

· Current research literature in journals including Emerging Infectious Diseases, Clinical Microbiology Reviews, Journal of Clinical Microbiology, International Journal of Systematic and Evolutionary Microbiology, and Microbial Pathogenesis

---

12. Further Study: Microbes and Interventions That Might Interest You Due to Similar Properties

Lactobacillus Species

Phylum: Bacillota (Family Lactobacillaceae)

Similarities: Like the probiotic applications of A. viridans, Lactobacillus species produce hydrogen peroxide and exhibit antimicrobial activity against uropathogens. They are established probiotics for urogenital health with extensive safety records. The hydrogen peroxide-producing capacity of certain Lactobacillus strains underlies their use in prevention of urinary tract infections and bacterial vaginosis.

Bacillus subtilis

Phylum: Bacillota (Family Bacillaceae)

Similarities: B. subtilis is used as a probiotic in combination with A. viridans 167 in associative probiotic complexes. The combination shows enhanced antimicrobial activity compared to either strain alone, demonstrating synergistic effects. B. subtilis produces multiple antimicrobial compounds including bacteriocins and has a well-established safety profile.

Enterococcus Species

Phylum: Bacillota (Family Enterococcaceae)

Similarities: Like Aerococcus species, enterococci were historically misidentified as streptococci and exhibit dual nature as both commensals and opportunistic pathogens. Some Enterococcus strains have probiotic applications while others cause healthcare-associated infections. The genus parallels Aerococcus in the need for careful strain selection and safety assessment.

Hydrogen Peroxide-Producing Probiotics

Intervention: Probiotics with antimicrobial mechanisms

Similarities: Hydrogen peroxide production is a key mechanism of antagonism for A. viridans. Other hydrogen peroxide-producing bacteria, including certain Lactobacillus and Streptococcus species, are used for urogenital and gastrointestinal health. Understanding this mechanism informs probiotic selection for infection prevention.

Bacteriocin-Producing Probiotics

Intervention: Probiotics with antimicrobial peptides

Similarities: The antimicrobial activity of A. viridans against multiple pathogens parallels that of bacteriocin-producing probiotics. Bacteriocins are ribosomally synthesized antimicrobial peptides that inhibit closely related bacteria, offering potential alternatives to conventional antibiotics.

---

Disclaimer

Aerococcus species, including Aerococcus viridans, are primarily recognized as emerging human pathogens. While in vitro research has identified potential probiotic properties including antimicrobial activity, antioxidant effects, and anti-cancer activity, these applications remain investigational. No Aerococcus-based probiotics are currently approved for human use in major regulatory jurisdictions. The use of live Aerococcus preparations carries potential risks including infection, particularly in vulnerable populations. The anti-cancer findings derive from in vitro studies and require validation in animal models and human trials before clinical application. This information is for educational purposes only and is not a substitute for professional medical advice. Any therapeutic use of Aerococcus species should only be considered within approved clinical trials with appropriate safety monitoring.